Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herombopag Olamine for breast cancer therapy-induced thrombocytopenia (observational)
ChiCTR2100053670Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hetrombopag in Thrombocytopenia, sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Platelet count. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
hetrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on ChiCTR2100053670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053670.